Antineuropathic Profile of N-Palmitoylethanolamine in a Rat Model of Oxaliplatin-Induced Neurotoxicity
Fig 5
Inflammation-related mediators.
On day 21, protein expression levels of IκBα were quantified by immunoblot in a) DRG and b) spinal cord; c) protein expression levels of COX2 were quantified by immunoblot in spinal cord Animals were treated daily i.p. with 2.4 mg kg-1 oxaliplatin or vehicle for 21 days. PEA (30 mg kg-1) was repeatedly administered i.p. (daily for 20 days starting from the first day of oxaliplatin administration). Control animals were treated with vehicles. Densitometric analysis is shown. β-actin normalization was performed for each sample. Each value represents the mean of 5 rats per group, performed in two different experimental sets. ^P<0.05 and ^^P<0.01 versus oxaliplatin + vehicle.